Company
Board of Directors
Company
Co-Founder, Chairperson & Chief Executive Officer
Dr. Tehila Ben Moshe is the CEO and co-founder of Biond Biologics and has led the company since its inception. She brings over a decade of leadership experience in biotech and pharma, combining deep scientific expertise with strong business acumen.
Prior to Biond, Dr. Ben Moshe was CEO of cCAM Biotherapeutics, where she led the company from inception through early clinical development, culminating in its acquisition by Merck (MSD) in 2015.
At Biond, she played a central role in securing a strategic partnership with Sanofi for BND-22, including a $125M upfront payment and up to ~$1B in milestones, validating the company’s scientific approach and development capabilities.
Dr. Ben Moshe holds a Ph.D. in Biochemistry from the Weizmann Institute and undergraduate degrees in Neuroimmunology and Biotechnology from Bar-Ilan University and the Hebrew University. She is an inventor on multiple patents and has authored several peer-reviewed publications.
Co-Founder & Chief Financial Officer
Ori Shilo is a co-founder of Biond Biologics and serves as Chief Financial Officer and Board Member since the company’s inception. He brings over two decades of experience in investment banking and strategic advisory within the pharma and biotech sectors.
Ori played a key role in advancing Biond’s global partnership with Sanofi for BND-22, overseeing transactions that generated over $120 million in upfront payments and reflecting his strong track record in structuring high-value collaborations.
Prior to Biond, Ori was instrumental in the establishment of RedHill Biopharma (NASDAQ: RDHL), where he served as CFO, Deputy CEO, and Director.
During his tenure, he led the company’s IPO on the Tel Aviv Stock Exchange and its subsequent dual listing on NASDAQ, while securing over $100 million in financing across private and public rounds and supporting the advancement of multiple Phase 2 and Phase 3 clinical programs.
Earlier in his career, Ori was a partner at ProSeed Capital Holding CVA, where he managed investments and banking activities in Israel.
General partner at Evergreen, Owner EthosVentures
Ronit has served as a member of our Board of Directors since 2017. Ronit is a general partner at Evergreen, focuses on investments in the healthcare sector. Since 2014 she has also been an early-stage private investor through EthosVentures. Before joining Evergreen, Ronit served as Vice President of Pharmos Ltd. (NASDAQ: PARS). Prior to that Ronit held senior positions at InterPharm Ltd. (Israel) and Ares-Serono (Switzerland). Ronit is a member of the board of Directors of I-Next-Tech, the tech transfer unit of Tel Aviv-Yaffo Sourasky medical center and on the board directors of Schwartz/Reisman Science Education foundation. She has taught industrial aspects of BioMed entrepreneurship in the Weizmann Institute and the Hebrew University as well as at the Israeli Medical Association. Ronit holds a PhD in molecular and cellular biology from the Weizmann Institute of Science
Co-founder and managing Partner, Israel Biotech Fund
Yuval has served as a member of our Board of Directors since 2021. He is the co-founder and Managing Partner of Israel Biotech Fund, a venture capital fund investing in exceptional Israeli pharmaceutical companies. Yuval serves on the Board of Directors of Pharma Two B and Tamarix. He is also the co-founder and a Board Member of 8400 – The Health Network. Dr. Cabilly received his PhD in molecular cell biology from the Tel Aviv University. His research focused on neurodegenerative diseases.
VP, Managing Director, Harel Insurance & Finance
Tomer has served as a member of our Board of Directors since 2021. He joined Harel in 2021 to lead the technology investment practice. Before that, Tomer was part of Cisco Investments, focusing on the full range of strategic initiatives, including acquisitions and investments, that Cisco pursues in Israel. Prior to Cisco, Tomer was at Audible, an Amazon company, as a Senior Product Manager focused on web and mobile apps, and before that, Tomer was at Deloitte Consulting working with Technology, Media and Telecom clients. Tomer began his career in the Israeli Defense Forces’ UAV (Unmanned Aerial Vehicles) unit as a pilot and officer. Tomer holds an MBA from Columbia University’s Business School and an LLB from the University of Haifa, Israel.
Co-founder and managing Partner, Deep Insight
Barak has served as a member of our Board of Directors since 2021. He is the co-founder and Managing Partner of Deep Insight, a private fund investing only in Israeli deep tech companies. Barak serves on the Board of Directors of Anima Biotech and Biolojic Design. Barak was the commander of TALPIOT Program (IDF) and the VP of XIV, one of the successful exists sold to IBM. Barak is one of the founders of the “President’s Program for Nurturing the State of Israel’s Future Scientists and Inventors”, the founder of the “Einstein Network” – a global network for the future of mankind and was a special advisor in the fields of Strategy and Technology to the Police Commissioner and to the National Security Council. Barak holds a bachelor’s degree in mathematics, Physics and Computers, and a master’s degree in history, Philosophy and Sociology of Science from the Hebrew University in Jerusalem.
Director of the Davidoff Comprehensive Cancer Center, Founder and Chairman of the Samueli Integrative Cancer Pioneering Institute, and Deputy CEO of Rabin Medical Center. Full Professor of Cancer Immunology at Tel Aviv University and a board-certified medical oncologist.
Prof. Markel is a globally recognized expert in skin cancers and immuno-oncology, with over 150 scientific publications and more than 30 patents. His notable contributions include the discovery of CEACAM1 as an immune checkpoint and pioneering work on fecal microbiota transplantation as an immunomodulatory approach in immunotherapy-refractory melanoma.
He has founded multiple biotech companies, including ventures acquired by MSD and DSPG, and currently supports additional companies advancing toward clinical development. Prof. Markel serves on several national and international scientific and advisory boards and is a frequent invited speaker at leading conferences, including AACR, ESMO, and TEDMED.